A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6712 participants.
Also called NCT06424288
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 6,712 participants
- Sponsor
- Registry
-
NCT06424288 -
2023-509706-30-00 -
U1111-1302-4422
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Serbia, Slovenia, South Africa, South Korea, Spain, Taiwan, Türkiye, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT06424288. Randomized; triple masking; primary purpose treatment. Start 2024-06-17 (actual); primary completion 2028-05-22 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
- Condition
- Heart Failure
- Intervention (Drug)
- vicadrostat
- Intervention (Drug)
- empagliflozin
- Intervention (Drug)
- placebo
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct06424288- Content hash
89f25c14d8f5902cd4ce84cb295a6a9975b2e15ba267e404bacabfc7370f9778